236 related articles for article (PubMed ID: 32843493)
1. HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery.
Katz SC; Moody AE; Guha P; Hardaway JC; Prince E; LaPorte J; Stancu M; Slansky JE; Jordan KR; Schulick RD; Knight R; Saied A; Armenio V; Junghans RP
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32843493
[TBL] [Abstract][Full Text] [Related]
2. HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA
Katz SC; Hardaway J; Prince E; Guha P; Cunetta M; Moody A; Wang LJ; Armenio V; Espat NJ; Junghans RP
Cancer Gene Ther; 2020 May; 27(5):341-355. PubMed ID: 31155611
[TBL] [Abstract][Full Text] [Related]
3. Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.
Katz SC; Burga RA; McCormack E; Wang LJ; Mooring W; Point GR; Khare PD; Thorn M; Ma Q; Stainken BF; Assanah EO; Davies R; Espat NJ; Junghans RP
Clin Cancer Res; 2015 Jul; 21(14):3149-59. PubMed ID: 25850950
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases.
Saied A; Licata L; Burga RA; Thorn M; McCormack E; Stainken BF; Assanah EO; Khare PD; Davies R; Espat NJ; Junghans RP; Katz SC
Cancer Gene Ther; 2014 Nov; 21(11):457-62. PubMed ID: 25277132
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
6. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
[TBL] [Abstract][Full Text] [Related]
7. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA
Zhang C; Wang Z; Yang Z; Wang M; Li S; Li Y; Zhang R; Xiong Z; Wei Z; Shen J; Luo Y; Zhang Q; Liu L; Qin H; Liu W; Wu F; Chen W; Pan F; Zhang X; Bie P; Liang H; Pecher G; Qian C
Mol Ther; 2017 May; 25(5):1248-1258. PubMed ID: 28366766
[TBL] [Abstract][Full Text] [Related]
8. Locoregional delivery of CAR-T cells in the clinic.
Sagnella SM; White AL; Yeo D; Saxena P; van Zandwijk N; Rasko JEJ
Pharmacol Res; 2022 Aug; 182():106329. PubMed ID: 35772645
[TBL] [Abstract][Full Text] [Related]
9. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
Hege KM; Bergsland EK; Fisher GA; Nemunaitis JJ; Warren RS; McArthur JG; Lin AA; Schlom J; June CH; Sherwin SA
J Immunother Cancer; 2017; 5():22. PubMed ID: 28344808
[TBL] [Abstract][Full Text] [Related]
10. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T.
Burga RA; Thorn M; Point GR; Guha P; Nguyen CT; Licata LA; DeMatteo RP; Ayala A; Joseph Espat N; Junghans RP; Katz SC
Cancer Immunol Immunother; 2015 Jul; 64(7):817-29. PubMed ID: 25850344
[TBL] [Abstract][Full Text] [Related]
11. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.
Cha SE; Kujawski M; J Yazaki P; Brown C; Shively JE
Oncoimmunology; 2021 Mar; 10(1):1899469. PubMed ID: 33796409
[TBL] [Abstract][Full Text] [Related]
12. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study.
Qian S; Chen J; Zhao Y; Zhu X; Dai D; Qin L; Hong J; Xu Y; Yang Z; Li Y; Guijo I; Jiménez-Galanes S; Guadalajara H; García-Arranz M; García-Olmo D; Shen J; Villarejo-Campos P; Qian C
Cytotherapy; 2024 Feb; 26(2):113-125. PubMed ID: 37999667
[TBL] [Abstract][Full Text] [Related]
14. Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis Model.
Chai LF; Hardaway JC; Heatherton KR; O'Connell KP; LaPorte JP; Guha P; Lopes MC; Rabinowitz BA; Jaroch D; Cox BF; Knight R; Katz SC
J Surg Res; 2022 Apr; 272():37-50. PubMed ID: 34929499
[TBL] [Abstract][Full Text] [Related]
15. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
Bagley SJ; O'Rourke DM
Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
[TBL] [Abstract][Full Text] [Related]
16. Prospects and challenges for use of CAR T cell therapies in solid tumors.
Ramakrishna S; Barsan V; Mackall C
Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
[No Abstract] [Full Text] [Related]
17. Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma.
Guo J; Tang Q
Cancer Gene Ther; 2021 Nov; 28(10-11):1075-1087. PubMed ID: 33500535
[TBL] [Abstract][Full Text] [Related]
18. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma.
Liu G; Rui W; Zheng H; Huang D; Yu F; Zhang Y; Dong J; Zhao X; Lin X
Eur J Immunol; 2020 May; 50(5):712-724. PubMed ID: 31981231
[TBL] [Abstract][Full Text] [Related]
19. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery.
Katz SC; Point GR; Cunetta M; Thorn M; Guha P; Espat NJ; Boutros C; Hanna N; Junghans RP
Cancer Gene Ther; 2016 May; 23(5):142-8. PubMed ID: 27080226
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
